Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of SIX6 as a Universal Cancer Marker in the Diagnosis of Non-Muscle Invasive Bladder Cancer

NCT07252297 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT07252297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07252297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of SIX6 as a Universal Cancer Marker in the Diagnosis of Non-Muscle Invasive Bladder Cancer
Lead sponsor
Xijing Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
March 18, 2025
Completion date
December 30, 2026
Enrollment
177 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer